on the basis of in vitro studies demonstrating marked synergy between mitoxantrone and high-dose cytosine arabinoside ( ara-c ) ( hidac ) against l5178y murine leukemia and clinical studies showing usefulness of the combination in patients with refractory acute myeloid leukemia , a phase i study was initiated to find tolerable doses for use in patients with refractory solid tumors .
C0026259
mitoxantrone
C0023467
acute myeloid leukemia